scholarly journals High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

2007 ◽  
Vol 2007 ◽  
pp. 1-6 ◽  
Author(s):  
Michael J. Veness

Nonmelanoma skin cancers (squamous cell and basal cell carcinomas) occur at an epidemic rate in many countries with the worldwide incidence increasing. The sun-exposed head and neck are the most frequent sites for these cancers to arise and in most patients diagnosed with a cutaneous squamous cell carcinoma, local treatment is usually curative. However, a subset is diagnosed with a high-risk cutaneous squamous cell carcinoma. High-risk factors include size (> 2 cm), thickness/depth of invasion (> 4 mm), recurrent lesions, the presence of perineural invasion, location near the parotid gland, and immunosuppression. These patients have a higher risk (> 10–20%) of developing metastases to regional lymph nodes (often parotid nodes), and in some cases also of experiencing local morbidity (perineural invasion), based on unfavourable primary lesion and patient factors. Despite treatment, many patients developing metastatic cutaneous squamous cell carcinoma experience mortality and morbidity usually as a consequence of uncontrolled metastatic nodal disease. It is therefore important that clinicians treating nonmelanoma skin cancers have an understanding and awareness of these high-risk patients. The aim of this article is to discuss the factors that define a high-risk patient and to present some of the issues pertinent to their management.

Pathology ◽  
2017 ◽  
Vol 49 (5) ◽  
pp. 494-498 ◽  
Author(s):  
Laveniya Satgunaseelan ◽  
Noel Chia ◽  
Hyerim Suh ◽  
Sohaib Virk ◽  
Bruce Ashford ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e21043-e21043
Author(s):  
Mary Stevenson ◽  
Alexis Santana ◽  
Nicole Adell Doudican ◽  
Theresa N Canavan ◽  
Anna C. Pavlick ◽  
...  

e21043 Background: Perineural invasion (PNI) is associated with a high risk for recurrence and metastasis from cutaneous squamous cell carcinoma (cSCC). Recommendations vary regarding use of post-operative radiation therapy (PORT). Biomarkers for poor outcome from cSCC with PNI are lacking. We aimed to evaluate outcomes in high-risk cSCC with PNI treated surgically +/- PORT and to evaluate tissue from the primary tumor to identify biomarkers for highest risk. Methods: We conducted a retrospective chart review of PNI SCC patients seen between 2005 and 2014. We compared outcomes for surgery vs. surgery plus PORT. Gene expression from tumor debulk was evaluated via Nanostring. MAGEA3 function was evaluated using PAM 212 SCC cells in a BALB/c mouse model. CRISPR-Cas9 MAGEA3 PAM 212 knockouts were developed to assess role of MAGEA3 in SCC growth. Results: Thirty-two patients with PNI SCC were identified. All were treated surgically, and 18/32 elected to undergo PORT. Nodal metastases were noted in 5/14 patients who did not undergo PORT, whereas no metastases were noted in any patient who underwent PORT. Thus, surgery plus PORT was associated with better outcome than surgery alone (P < 0.01). Local recurrence was not observed in any patients treated by surgery, including 30 patients treated by Mohs micrographic surgery (MMS). MAGEA3 was highly expressed in PNI SCC. MAGEA3 expression in PAM 212 SCC was associated with tumor growth and increased expression of cyclins A, B, and E. CRISPR-Cas9 MAGEA3 PAM 212 knockouts exhibited reduced growth in BALB/c mice. Conclusions: MAGEA3 expression is increased in human PNI SCC. We can mitigate against worst case outcome with surgery plus PORT. MAGEA3 merits further investigation as a potential biomarker for best candidates for surgery plus PORT.


Head & Neck ◽  
2015 ◽  
Vol 38 (S1) ◽  
pp. E884-E889 ◽  
Author(s):  
Sinclair M. Gore ◽  
Douglas Shaw ◽  
Richard C. W. Martin ◽  
Wendy Kelder ◽  
Kathryn Roth ◽  
...  

2020 ◽  
Vol 156 (8) ◽  
pp. 918
Author(s):  
Mary L. Stevenson ◽  
Maressa C. Criscito ◽  
Reason Wilken ◽  
Nicole A. Doudican ◽  
Earl Eugene Bain ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document